{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:10:28Z","timestamp":1793171428599,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.clinthera.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T16:00:28Z","timestamp":1567094428000},"page":"1576-1588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review"],"prefix":"10.1016","volume":"41","author":[{"given":"Patrice","family":"Fardellone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Lello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"de S\u00e1 Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Watanabe de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Silva","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boxiong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.05.001_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2019.05.001_bib2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society","volume":"17","year":"2010","journal-title":"Menopause"},{"key":"10.1016\/j.clinthera.2019.05.001_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.clinthera.2019.05.001_bib5","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","article-title":"Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting","volume":"28","author":"Kanis","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00198-012-2179-3","article-title":"A\u00a0meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women","volume":"24","author":"Yates","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib7","first-page":"CD001155","article-title":"Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women","volume":"1","author":"Wells","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2019.05.001_bib8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.clinthera.2019.05.001_bib9","first-page":"37","article-title":"The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis","volume":"24","author":"Byun","year":"2017","journal-title":"J\u00a0Bone Metab"},{"key":"10.1016\/j.clinthera.2019.05.001_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bone.2013.09.023","article-title":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review","volume":"58","author":"Eriksen","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2019.05.001_bib11","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","article-title":"Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib12","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00198-009-1134-4","article-title":"Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis","volume":"21","author":"Imaz","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A\u00a0systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib14","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.clinthera.2019.05.001_bib15","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00198-012-2108-5","article-title":"Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice","volume":"24","author":"Weycker","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2019.05.001_bib17","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s00198-016-3683-7","article-title":"Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries","volume":"27","author":"Kjellberg","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.05.001_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.05.001_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","article-title":"Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis","volume":"21","author":"Cotte","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/jech.2008.084558","article-title":"Uptake of treatment for osteoporosis and compliance after bone density measurement in the community","volume":"64","author":"Dugard","year":"2010","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.clinthera.2019.05.001_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jep.12422","article-title":"The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink","volume":"22","author":"Ferguson","year":"2016","journal-title":"J\u00a0Eval Clin Pract"},{"key":"10.1016\/j.clinthera.2019.05.001_bib23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","article-title":"GRAND: the German retrospective\u00a0cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.pec.2013.06.014","article-title":"Knowledge and health literacy are not associated with osteoporotic medication adherence, however income is, in Arab postmenopausal women","volume":"93","author":"Shehadeh-Sheeny","year":"2013","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.clinthera.2019.05.001_bib25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","article-title":"Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis","volume":"21","author":"Cramer","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.05.001_bib26","first-page":"56","article-title":"Cost and consequences of noncompliance to oral bisphosphonate treatment","volume":"21","author":"Eisenberg","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2019.05.001_bib27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1185\/03007995.2015.1016606","article-title":"Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment","volume":"31","author":"Modi","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.05.001_bib28","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","article-title":"Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women","volume":"19","author":"Rabenda","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","article-title":"Assessment of compliance with osteoporosis treatment and its consequences in a managed care population","volume":"38","author":"Huybrechts","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2019.05.001_bib30","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1185\/030079907X226069","article-title":"Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills","volume":"23","author":"Weiss","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2019.05.001_bib31","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s12325-016-0360-3","article-title":"Role of side effects, physician involvement, and patient perception in non-adherence with oral bisphosphonates","volume":"33","author":"Goldshtein","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.05.001_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/14737167.2016.1171145","article-title":"Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost","volume":"16","author":"Chodick","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2019.05.001_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2147\/TCRM.S52291","article-title":"Eliminating the need for fasting with oral administration of bisphosphonates","volume":"9","author":"Pazianas","year":"2013","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2019.05.001_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/rtph.1993.1067","article-title":"Toxicological profile, current use, and regulatory issues on EDTA compounds for assessing use of sodium iron EDTA for food fortification","volume":"18","author":"Whittaker","year":"1993","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.clinthera.2019.05.001_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","article-title":"Comparison of drug adherence rates among patients with seven different medical conditions","volume":"28","author":"Briesacher","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2019.05.001_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/WHE.14.15","article-title":"Can new information and communication technologies help in the management of osteoporosis?","volume":"10","author":"Slomian","year":"2014","journal-title":"Womens Health (Lond Engl)."},{"key":"10.1016\/j.clinthera.2019.05.001_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","article-title":"Loss of treatment benefit due to low compliance with bisphosphonate therapy","volume":"19","author":"Penning-van Beest","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib38","first-page":"207","article-title":"Factors contributing to compliance with osteoporosis medication","volume":"10","author":"Kertes","year":"2008","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.clinthera.2019.05.001_bib39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1060028015626935","article-title":"Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis","volume":"50","author":"Sharman Moser","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2019.05.001_bib40","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00198-014-2774-6","article-title":"Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital's fracture liaison service between January 2010 and December 2011","volume":"25","author":"Dehamchia-Rehailia","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2019.05.001_bib41","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2019.05.001_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/pds.3718","article-title":"Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data","volume":"24","author":"Burden","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2019.05.001_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2474-14-4","article-title":"Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study","volume":"14","author":"Hazel-Fernandez","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2019.05.001_bib44","first-page":"503","article-title":"Predicting adherence and persistence with oral bisphosphonate therapy in an integrated health care delivery system","volume":"23","author":"Hui","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2019.05.001_bib45","doi-asserted-by":"crossref","first-page":"11784","DOI":"10.1038\/s41598-017-10899-6","article-title":"Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study","volume":"7","author":"Garcia-Sempere","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2019.05.001_bib46","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1007\/s00198-013-2326-5","article-title":"Primary non-adherence to bisphosphonates in an integrated healthcare setting","volume":"24","author":"Reynolds","year":"2013","journal-title":"Osteoporos Int"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819302462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819302462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:37Z","timestamp":1758963097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819302462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0149291819302462"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}